Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.

摘要: The combination of venetoclax with hypomethylating agents (VEN-HMAs) showed promising activity in newly diagnosed and relapsed/refractory (r/r) acute myeloid leukemia (AML). Treatment VEN-HMAs results prolonged cytopenia, thereby exposing patients to invasive fungal infections (IFIs). Here, we retrospectively studied a cohort 119 AML treated analyzed the occurrence IFIs, as well our practice antifungal prophylaxis, aim identify nature risk factors for IFIs their association type prophylaxis used. intended was micafungin 38% patients, azoles 41% none 21% patients. Older age associated no or use lesser (P = .043). We recorded 15 (12.6%) who developed probable proven median onset 72 days (range, 35-281) after starting therapy. were more common among nonresponders compared responders VEN-HMA therapy (22% vs 6%, P .0132) r/r (19% 5%, .0498); however, used, patient age, agent schedule, history prior allogeneic transplant, initial neutropenia duration did not influence development during conclude that overall is low. higher those setting; these need reevaluation minimize